Wedbush Issues Pessimistic Estimate for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Wedbush dropped their Q1 2025 earnings estimates for shares of Neurocrine Biosciences in a research note issued on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the company will post earnings of $1.44 per share for the quarter, down from their prior forecast of $1.52. Wedbush has a “Outperform” rating and a $148.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.93 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.75 EPS, Q3 2025 earnings at $1.85 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $7.23 EPS, FY2026 earnings at $9.89 EPS and FY2029 earnings at $21.23 EPS.

A number of other research firms have also weighed in on NBIX. Piper Sandler reaffirmed an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 23rd. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Raymond James restated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Finally, HC Wainwright restated a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.40.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $150.71 on Monday. The business’s fifty day moving average is $135.33 and its 200 day moving average is $131.30. The firm has a market cap of $15.26 billion, a price-to-earnings ratio of 40.40 and a beta of 0.33. Neurocrine Biosciences has a 52-week low of $110.95 and a 52-week high of $157.98.

Institutional Investors Weigh In On Neurocrine Biosciences

Large investors have recently made changes to their positions in the business. Golden State Wealth Management LLC purchased a new position in shares of Neurocrine Biosciences during the fourth quarter valued at about $25,000. Brooklyn Investment Group grew its holdings in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 115 shares during the period. Blue Trust Inc. raised its position in shares of Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares in the last quarter. R Squared Ltd bought a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $61,000. Finally, UMB Bank n.a. grew its stake in Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after purchasing an additional 309 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Kyle Gano sold 65,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the sale, the chief executive officer now directly owns 135,392 shares in the company, valued at approximately $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,694 shares of company stock valued at $9,676,730 in the last ninety days. Company insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.